Insulet has launched the Omnipod 5 automated insulin delivery app for iPhone in the US. The app obviates the need for carrying a separate controller as it allows users to manage their insulin ...

Modern insulin pumps are self-contained devices that attach to a user’s skin via an adhesive patch, and are responsible for administering insulin as needed. Curious as to what was inside, [Ido ...

Insulet first launched its Omnipod 5 patch-pump for people with Type 1 diabetes in 2022. Now, the device is also indicated for people with Type 2 diabetes ages 18 years and older.

The insulin pump is currently compatible with many Android devices, and Benjamin told Fierce Medtech that Insulet is currently working on an iPhone-friendly version of the app.

Total Omnipod revenue of $422 million marked a year-over-year increase of 29.4%. The company reported adjusted EPS of $0.71, beating the consensus of $0.40 and higher than $0.45 a year ago.

An insulin pump is an alternative to giving yourself multiple daily insulin injections. These can be used by people with type 1 or type 2 diabetes.

Label expansion makes Omnipod 5 commercially available to 6 million people living with insulin-requiring type 2 diabetes Omnipod 5 is the first and only automated insulin delivery (AID) system ...

State Sen. Carrie Hicks (D-Oklahoma City) wants Medicaid coverage for the Omnipod insulin pump to help make patients' lives better in Oklahoma.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products ...

The Food and Drug Administration on Monday approved Insulet's Omnipod 5 automated insulin delivery system for people with Type 2 diabetes.

JOHOR BAHRU, Aug 14 (Bernama) -- United States-based medical device company Insulet Corporation’s new manufacturing facility in Johor Bahru will position the company strategically to stay ahead of the ...

Omnipod 5 is setting a new standard in diabetes management, and we are thrilled with the opportunity to make a lasting impact on the insulin-requiring type 2 diabetes community.” ...